KAKEN PHARMACEUTICAL CO.,LTD.(4521) News

[Summary] Consolidated Financial Results for the Three Months Period of Fiscal 2025 (Three Month Period Ended June 30, 2025) [JGAAP]

Strategic Collaboration with Astria Therapeutics, Inc. to Develop and Commercialize Navenibart for Hereditary Angioedema in Japan

KAKEN PHARMA, Apr-Jun (1Q) Ordinary Profit Decreases by 86%

License Agreement for “gMSC1”, the Allogenic Synovial Mesenchymal Stem Cell-Derived Three-Dimensional Artificial Tissue

Notice of Implementation of Share Benefit Rules and Disposal of Treasury Stock by Third-Party Allotment

Notice Regarding Completion of Cancellation of Treasury Shares

KAKEN PHARMA, 72% Decrease in Ordinary Profit for The Current Fiscal Year

[Summary]Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 [JGAAP]

Notice Regarding Differences Between Non-Consolidated Financial Results and Results for the Previous Fiscal Year

Updates on Actions to Implement Management that is Conscious of Cost of Capital and Stock Price

Notice Regarding Completion of Acquisition of Treasury Shares

Partnership and License Agreement for the Commercialization of Sebetralstat for Hereditary Angioedema in Japan

Partial Revision of Long-Term Business Plan 2031

Revision to Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2025

KAKEN PHARMA, Last Fiscal Year Ordinary Profit Revised Downward by 1%

Notice Regarding Acquisition of Treasury Shares

[Summary]Consolidated Financial Results for the Nine-Months Period of Fiscal 2024 (Nine-Month Period Ended December 31, 2024) [JGAAP]

KAKEN PHARMA, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 2.8 times, Exceeds Full-Year Plan

KAKEN PHARMACEUTICAL CO.,LTD., First Half Ordinary Profit Increases by 3.5 times, July-September Ordinary Profit Increases by 7.5 times

[Summary]Consolidated Financial Results for the Six-Months Period of Fiscal 2024 (Six-Month Period Ended September 30, 2024) [JGAAP]